Necessity of identifying the patterns of failure after concurrent radiochemotherapy part of a combined modality approach in patients with stage III non-small cell lung cancer [Sakai et al., Lung Cancer 2004;43:195-201].
Branislav
B
Jeremic
Frank
F
Zimmermann
Carsten
C
Nieder
Michael
M
Molls
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D000077143:Docetaxel; D023381:Endpoint Determination; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010347:Patient Care Planning; D011379:Prognosis; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
D043823:Taxoids; D000077143:Docetaxel; D016190:Carboplatin